Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response kinetics and clinical benefits of nonintensive AML therapies in the absence of morphologic response
    Review

    Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Schuh, A. C.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
    Journal Article

    Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W.; Erba, H. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E. M.; Latremouille-Viau, D.; Joseph, G. J.; Shi, S.; Guerin, A.; Wu, E. Q.; Bonifacio, G.; Cao, X.
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: A phase II study
    Meeting Abstract

    Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; King, A. C.; Stein, E. M.; Pemmaraju, N.; Mauro, M. J.; Kadia, T. M.; Montalban-Bravo, G.; Alvarez, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ib/II study of the histone methyltransferase inhibitor pinometostat in combination with azacitidine in patients with 11q23-rearranged acute myeloid leukemia
    Meeting Abstract

    Menghrajani, K.; Cai, S. F.; Devlin, S. M.; Armstrong, S. A.; Piekarz, R.; Rudek, M.; Tallman, M. S.; Stein, E. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Bone marrow morphologic findings in patients receiving IDH inhibitor therapy in combination with intensive induction chemotherapy: Challenges with interpretation of the day 14 bone marrow biopsy
    Meeting Abstract

    Mason, E. F.; Pozdnyakova, O.; Roshal, M.; Fathi, A. T.; Stein, E. M.; Shaver, A. C.; Frattini, M. G.; Wang, H.; Hua, L.; Mu, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    Foran, J. M.; DiNardo, C. D.; Watts, J. M.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A.; Stone, R. M.; Patel, P. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Improved overall survival with enasidenib compared with standard of care among patients with relapsed or refractory acute myeloid leukemia and IDH2 mutations: A propensity score matching analysis using data from the AG221-C-001 trial and two data sources from France and Germany
    Meeting Abstract

    De Botton, S.; Brandwein, J. M.; Stein, E. M.; Wei, A. H.; Weber, D.; Pigneux, A.; Boissel, N.; Paschka, P.; DoĢˆhner, K.; Nehme, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High rate of IDH1 mutation clearance and measurable residual disease negativity in patients with IDH1-mutant newly diagnosed acute myeloid leukemia treated with ivosidenib (AG-120) and azacitidine
    Meeting Abstract

    Daigle, S. R.; Choe, S.; Quek, L.; DiNardo, C. D.; Stein, A.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Kantarjian, H. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Newly diagnosed AML patient samples demonstrate high degree of concordance in identification of pathogenic mutations by next generation sequencing (NGS) performed at enrolling institutions compared to central laboratory results in the Beat AML Master Trial
    Meeting Abstract

    Borate, U.; Ruppert, A. S.; Yang, F.; Jones, D.; Caruthers, S.; Zhao, W.; Vergilio, J. A.; Burd, A.; Pavlick, D.; Juckett, L.; more...
    Blood (2019)

    Fulltext@MSK | Save